34 results on '"Al-Hussaini, T"'
Search Results
2. Seismic Strengthening Solutions for Existing Buildings
- Author
-
Al-Hussaini, T. M., Hoque, M. M., Moghadam, A. S., Chen, Sheng-Hong, Series Editor, di Prisco, Marco, Series Editor, Vayas, Ioannis, Series Editor, Kolathayar, Sreevalsa, editor, Pal, Indrajit, editor, Chian, Siau Chen, editor, and Mondal, Arpita, editor
- Published
- 2022
- Full Text
- View/download PDF
3. Seismic Strengthening Solutions for Existing Buildings
- Author
-
Al-Hussaini, T. M., primary, Hoque, M. M., additional, and Moghadam, A. S., additional
- Published
- 2021
- Full Text
- View/download PDF
4. The Cost Implications in Ontario, Alberta, and British Columbia of Early Versus Delayed External Cephalic Version in the Early External Cephalic Version 2 (EECV2) Trial
- Author
-
Hutton, E.K., Barrett, J., Carson, G.D., Delisle, M.F., Dunn, M., Edwards, S., Fernandez, A., Gafni, A., Hannah, M.E., Hewson, S., Natale, R., Ohlsson, A., Ross, S.J., Willan, A.R., Windrim, R., Pollard, J.K., Schweitzer, Sylvestre, G., Turtle, P., Bracken, M., Crowley, P., Donner, A., Duley, L., Ehrenkranz, R., Curioni, M., Abalos Gorostiaga, R., Becker, C., Elizabeth, P.A., Errandonea, L., Palermo, M., Ramos, C.A., Trabucco, M., Montes Varela, D., Bertin, M.S., Castaldi, J.L., Mohedano de Duhalde, M., Messina, A., Baumgartner, J., Kovacs, G., Malcolm, B., Neil, J.R., Mahomed, K., Green, A., Child, A., DeVries, B., Phipps, H., Welsh, A., Davis, G.K., Roberts, L., Watts, N.P., Cybulski, M., Gibson, D., Tucker, S., McCahon, I., Sheehan, P., Umstad, M., Milligan, J., Morris, J., Rickard, K., Gardener, G., Jenkins-Manning, S., Boniface, C., Edmondson, M., Watson, D., Ayub, A., Soanes, S., Jordan, A., Fanning, C., Parish, B., Watson, M.A., Reid, D., Scheufler, P., Malott, A.M., Reitsma, A., Haslauer, K.A., Lipp, M., Farquharson, D., Gray, K., Demianczuk, N., Penttinen, E., Herer, E., McLean, K., Aghajafari, F., Williams, S., Moravac, C., Yudin, M., Pollard, J., Miller, L., Anderson, R.B., Good, M., Walker, M.C., Kulkarni, R., Scarfone, R., Cameron, C., Peel, T., Carrillo, J., Cruces, A., Gonzalez, Y., Figueroa Poblete, J., Lama Hormazabal, L., Saez, J., Oyarzun, E., Rioseco, A., Illanes, S., Kottmann, C., Parra, M., Quezada, S., Quiroz, L., Hvidman, L., Mogensen, I.M., Mouritzen, A., Ostberg, B., Abdel-Samad, S.N.M., Al-Hussaini, T., El-Nashar, I., Kirss, F., Rull, K., Ustav, E., Vaas, P., Brink-Spalink, V., Weizsaecker, K., Major, T., Poka, R., Daly, S., Kaneti, H., Rosen, D., Schachter, B., Chayen, B., Harel, L., Hiaeb, Z., Malinger, G., Dukler, D., Lunenfeld, E., AlFaris, L., El-Zibdeh, M., Domzalska-Popadiuk, I., Kobiela, P., Pankrac, Z., Preis, J., Preis, K., Swiatkowska-Freund, M., Cravo, J., Theron, A.M., Theron, G.B., Cronje, H.S., du Plessis, J.M., Munoz, M., Khan, G., Khan, S., Goossens, S., Pieters, M., Roumen, F.J.M.E., ten Cate, F., Smits, F., Heres, M., Krabbendam, E., Airey, R., Farrar, D., Tuffnell, D.J., Heyes, V., Melvin, C., Schram, C., Galimberti, A., Stewart, P., Cresswell, J., McCormick, C., Andrews, J., Fleener, D., Coonrod, D., Jimenez, B.F., Brown, S., Gregg, A., Pitchford, C., Seubert, D., Ahmed, Rashid J., Gafni, Amiram, and Hutton, Eileen K.
- Published
- 2016
- Full Text
- View/download PDF
5. Assessment of the Dynamic Behaviour of the Jamuna Multipurpose Bridge Through Noise Study
- Author
-
Ahsan, R., primary, Ansary, M. A., additional, Al-Hussaini, T. M., additional, and Rahman, S. Z., additional
- Published
- 2007
- Full Text
- View/download PDF
6. Titrated low-dose vaginal and/or oral misoprostol to induce labour for prelabour membrane rupture: a randomised trial
- Author
-
Bricker, L, Peden, H, Tomlinson, A J, Al-Hussaini, T K, Idama, T, Candelier, C, Luckas, M, Furniss, H, Davies, A, Kumar, B, Roberts, J, and Alfirevic, Z
- Published
- 2008
- Full Text
- View/download PDF
7. Pregnancies following transvaginal gamete intrafallopian transfer (GIFT), zygote intrafallopian transfer (ZIFT), and tubal embryo-stage transfer (TEST) in an in vitro fertilization (IVF) program
- Author
-
Al-Hussaini, T., Mettler, L., Ibrahim, M., and Buck, S.
- Published
- 1992
- Full Text
- View/download PDF
8. The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for women at 2 years
- Author
-
Duley, L, Farrell, B, Armstrong, N, Spark, P, Roberts, B, Smyth, R, Tivnan, M, Laws, A, Corfield, N, Salter, A, Thorn, L, Altman, D, Yu, L-M, Abalos, E, Carroli, B, Dellepiane, L, Duarte, M, Fernandez, H, Giordano, D, Clarke, M, Gray, A, Hey, E, Neilson, J, Simon, J, Collins, R, Karaoglou, A, Lilford, R, Moodley, J, Robson, S, Roberts, I, Rubin, P, Thornton, J, Twaddle, S, Villar, J, Walker, I, Watkins, C, Doyle, L, Bimbashi, A, Demalia, E, Gliozheni, O, Shpata, A, Karolinski, A, Lamas, M, Pesaresi, M, Wainer, V, Barbato, W, Paciocco, M, Bertin, M, Boiza, E, Castaldi, J, Partida, Y, Arias, C, Farri, M, Kerz, G, Aguirre, J, de Sagastizabal, M, Falcone, R, Morales, E, Carroli, G, Krupitzky, S, Lopez, S, Palermo, M, Varela, DM, Delprato, H, Camusso, H, Curioni, M, Ludmer, E, Brandi, R, Martin, R, Mesas, W, Taralli, R, Lezaola, M, Morosini, M, Andina, E, Bernal, L, Estiu, M, Ulens, E, de Speranza, BO, Peyrano, A, Damiano, M, Saumench, C, Horn, J, Pritchard, M, Smith-Orr, V, Wilson, M, Lawrence, A, Watson, D, Crowther, C, Paynter, J, Mannan, M, Shahidullah, M, Shamsuddin, L, Santos, CB, Freire, S, Melo, E, Cobo, E, Jaramillo, M, Cardozo, C, Fandino, N, Gaitan, H, Montano, L, Lozano, J, Rojas, M, Garcia, AB, Ramirez, AF, Miras, RG, Sampera, S, Farnot, U, Gomez, E, Rojas, G, Valdes, R, El-Kreem, HA, Al-Hussaini, T, Hammad, E, Danso, K, Kwapong, E, Ofosu-Barko, F, Jasper, MP, Peedicayil, A, Regi, A, Sharma, R, Chauhan, A, Raut, V, Udani, R, Batra, S, Muthal-Rathore, A, Ramji, S, Zutshi, V, Balakrishnan, S, Eapen, E, Koshy, G, Ambardar, B, Vadakkepat, P, Vaidya, D, Lema, V, Rijken, Y, Tadesse, E, Dada, O, Sofekun, A, Ohiaeri, C, Runsewe-Abiodun, T, Adewole, I, Adeyemo, A, Brown, B, Oladokun, R, Adewale, O, Inimgba, N, John, C, Ogu, R, Ekele, B, Isah, A, Onankpa, B, Jamelle, R, Junejo, D, Faiz, N, Gul, F, Sherin, A, Bangash, K, Mahmud, G, Masud, K, Tasneem, N, Gassama, S, Soyei, A, Agarwal, P, Rajadurai, V, Pirani, N, Delport, S, Macdonald, P, Mokhondo, R, Pattinson, R, Zondo, M, Adhikari, M, Mnguni, N, Carstens, M, Kirsten, G, Steyn, W, van Zyl, J, Helwig, A, Jacobson, S-L, Panosche, R, Hammond, E, Masanganise, L, and Colla, MTF-US
- Subjects
Pediatrics ,medicine.medical_specialty ,Randomization ,pre-eclampsia ,magnesium sulphate ,Population ,Maternal Medicine ,Placebo ,law.invention ,Longterm follow-up ,Magnesium Sulfate ,Randomized controlled trial ,Interquartile range ,law ,Pregnancy ,Risk Factors ,Medicine ,Humans ,Maternal Health Services ,education ,Child ,education.field_of_study ,Eclampsia ,business.industry ,Pregnancy Outcome ,Obstetrics and Gynecology ,Patient Acceptance of Health Care ,medicine.disease ,randomised trial ,Clinical trial ,Maternal Mortality ,Relative risk ,Anticonvulsants ,Female ,business ,Follow-Up Studies - Abstract
Objective: The aim of this study was to assess long-term effects for women following the use of magnesium sulphate for pre-eclampsia. Design: Assessment at 2-3 years after delivery for women recruited to the Magpie Trial (recruitment in 1998-2001, ISRCTN 86938761), which compared magnesium sulphate with placebo for pre-eclampsia. Setting: Follow up after discharge from hospital at 125 centres in 19 countries across five continents. Population: A total of 7927 women were randomised at the follow-up centres. Of these women, 2544 were not included for logistic reasons and 601 excluded (109 at a centre where
- Published
- 2006
9. The Magpie Trial: a randomised trial comparing magnesium sulphate with placebo for pre-eclampsia. Outcome for children at 18 months
- Author
-
Duley, L, Farrell, B, Armstrong, N, Spark, P, Roberts, B, Smyth, R, Tivnan, M, Laws, A, Corfield, N, Salter, A, Thorn, L, Altman, D, Yu, L-M, Abalos, E, Carroli, B, Dellepiane, L, Duarte, M, Fernandez, H, Giordano, D, Clarke, M, Gray, A, Hey, E, Neilson, J, Simon, J, Doyle, L, Kelly, T, Squires, J, Collins, R, Karaoglou, A, Lilford, R, Moodley, J, Robson, S, Roberts, I, Rubin, P, Thornton, J, Twaddle, S, Villar, J, Walker, I, Watkins, C, Bimbashi, A, Demalia, E, Gliozheni, O, Shpata, A, Karolinski, A, Lamas, M, Pesaresi, M, Wainer, V, Barbato, W, Paciocco, M, Bertin, M, Boiza, E, Castaldi, J, Partida, Y, Farri, M, Kerz, G, Aguirre, J, de Sagastiza, M, Falcone, R, Morales, E, Carroli, G, Krupitzky, S, Lopez, S, Palermo, M, Varela, DM, Delprato, H, Camusso, H, Curioni, M, Ludmer, E, Brandi, R, Martin, R, Mesas, W, Taralli, R, Lezaola, M, Morosini, M, Andina, E, Bernal, L, Estiu, M, Ulens, E, de Speranza, BO, Peyrano, A, Damiano, M, Saumench, C, Horn, J, Pritchard, M, Smith-Orr, V, Wilson, M, Lawrence, A, Watson, D, Crowther, C, Paynter, J, Mannan, M, Shahidullah, M, Shamsuddin, L, Barros Santos, C, Freire, S, Melo, E, Cobo, E, Jaramillo, M, Cardozo, C, Fandino, N, Gaitan, H, Montano, L, Lozano, J, Rojas, M, Breto Garcia, A, Fuentes Ramirez, A, Garcia Miras, R, Sampera, S, Farnot, U, Gomez, E, Rojas, G, Valdez, R, El-Kreem, HA, Al-Hussaini, T, Hammad, E, Danso, K, Kwapong, E, Ofosu-Barko, F, Jasper, MP, Peedicayil, A, Regi, A, Sharma, R, Chauhan, A, Raut, V, Udani, R, Batra, S, Muthal-Rathore, A, Ramji, S, Zutshi, V, Balakrishnan, S, Eapen, E, Koshy, G, Ambardar, B, Vadakkepat, P, Vaidya, D, Lema, V, Rijken, Y, Tadesse, E, Dada, O, Sofekun, A, Ohiaeri, C, Runsewe-Abiodun, T, Adewole, I, Adeyemo, A, Brown, B, Oladokun, R, Adewale, O, Inimgba, N, John, C, Ogu, R, Ekele, B, Isah, A, Onankpa, B, Jamelle, R, Junejo, D, Faiz, NR, Gul, F, Sherin, A, Bangash, K, Mahmud, G, Masud, K, Tasneem, N, Gassama, S, Soyei, A, Agarwal, P, Rajadurai, V, Hani, C, Pirani, N, Delport, S, Macdonald, P, Mokhondo, R, Pattinson, R, Zondo, M, Adhikari, M, Mnguni, N, Carstens, M, Kirsten, G, Steyn, W, van Zyl, J, Helwig, A, Jacobson, S-L, Panosche, R, Hammond, E, Masanganise, L, and Collabor, MTFS
- Subjects
Pediatrics ,medicine.medical_specialty ,pre-eclampsia ,magnesium sulphate ,Maternal Medicine ,Placebo ,Preeclampsia ,law.invention ,Longterm follow-up ,Disability Evaluation ,Magnesium Sulfate ,Randomized controlled trial ,law ,Pregnancy ,medicine ,Humans ,reproductive and urinary physiology ,Cause of death ,Eclampsia ,business.industry ,Pregnancy Outcome ,Obstetrics and Gynecology ,Infant ,medicine.disease ,randomised trial ,female genital diseases and pregnancy complications ,Disabled Children ,Clinical trial ,In utero ,Prenatal Exposure Delayed Effects ,Sensation Disorders ,Anticonvulsants ,Female ,Nervous System Diseases ,business - Abstract
Objective To assess the long-term effects of in utero exposure to magnesium sulphate for children whose mothers had pre-eclampsia. Design Assessment at 18 months of age for children whose mothers were recruited to the Magpie Trial (recruitment 1998–2001 ISRCTN 86938761), which compared magnesium sulphate with placebo. Setting Follow-up of children born at 125 centres in 19 countries across five continents. Population A total of 6922 children were born to women randomised before delivery at follow-up centres. Of these, 2271 were not included for logistic reasons and 168 were excluded (101 at a centre where
- Published
- 2007
10. The Magpie Trial:: a randomised trial comparing magnesium sulphate with placebo for pre-eclampsia.: Outcome for women at 2 years
- Author
-
Duley, L, Farrell, B, Armstrong, N, Spark, P, Roberts, B, Smyth, R, Tivnan, M, Laws, A, Corfield, N, Salter, A, Thorn, L, Altman, D, Yu, L-M, Abalos, E, Carroli, B, Dellepiane, L, Duarte, M, Fernandez, H, Giordano, D, Clarke, M, Gray, A, Hey, E, Neilson, J, Simon, J, Collins, R, Karaoglou, A, Lilford, R, Moodley, J, Robson, S, Roberts, I, Rubin, P, Thornton, J, Twaddle, S, Villar, J, Walker, I, Watkins, C, Doyle, L, Bimbashi, A, Demalia, E, Gliozheni, O, Shpata, A, Karolinski, A, Lamas, M, Pesaresi, M, Wainer, V, Barbato, W, Paciocco, M, Bertin, M, Boiza, E, Castaldi, J, Partida, Y, Arias, C, Farri, M, Kerz, G, Aguirre, J, de Sagastizabal, M, Falcone, R, Morales, E, Carroli, G, Krupitzky, S, Lopez, S, Palermo, M, Varela, DM, Delprato, H, Camusso, H, Curioni, M, Ludmer, E, Brandi, R, Martin, R, Mesas, W, Taralli, R, Lezaola, M, Morosini, M, Andina, E, Bernal, L, Estiu, M, Ulens, E, de Speranza, BO, Peyrano, A, Damiano, M, Saumench, C, Horn, J, Pritchard, M, Smith-Orr, V, Wilson, M, Lawrence, A, Watson, D, Crowther, C, Paynter, J, Ashrafunnessa, Mannan, M, Shahidullah, M, Shamsuddin, L, Santos, CB, Freire, S, Melo, E, Cobo, E, Jaramillo, M, Cardozo, C, Fandino, N, Gaitan, H, Montano, L, Lozano, J, Rojas, M, Garcia, AB, Ramirez, AF, Miras, RG, Sampera, S, Farnot, U, Gomez, E, Rojas, G, Valdes, R, El-Kreem, HA, Al-Hussaini, T, Hammad, E, Danso, K, Kwapong, E, Ofosu-Barko, F, Jasper, MP, Peedicayil, A, Regi, A, Sharma, R, Chauhan, A, Raut, V, Udani, R, Batra, S, Muthal-Rathore, A, Ramji, S, Zutshi, V, Balakrishnan, S, Eapen, E, Koshy, G, Ambardar, B, Vadakkepat, P, Vaidya, D, Lema, V, Rijken, Y, Tadesse, E, Dada, O, Sofekun, A, Ohiaeri, C, Runsewe-Abiodun, T, Adewole, I, Adeyemo, A, Brown, B, Oladokun, R, Adewale, O, Inimgba, N, John, C, Ogu, R, Ekele, B, Isah, A, Onankpa, B, Jamelle, R, Junejo, D, Faiz, N, Gul, F, Sherin, A, Bangash, K, Mahmud, G, Masud, K, Tasneem, N, Gassama, S, Soyei, A, Agarwal, P, Rajadurai, V, Pirani, N, Delport, S, Macdonald, P, Mokhondo, R, Pattinson, R, Zondo, M, Adhikari, M, Mnguni, N, Carstens, M, Kirsten, G, Steyn, W, van Zyl, J, Helwig, A, Jacobson, S-L, Panosche, R, Hammond, E, Masanganise, L, Duley, L, Farrell, B, Armstrong, N, Spark, P, Roberts, B, Smyth, R, Tivnan, M, Laws, A, Corfield, N, Salter, A, Thorn, L, Altman, D, Yu, L-M, Abalos, E, Carroli, B, Dellepiane, L, Duarte, M, Fernandez, H, Giordano, D, Clarke, M, Gray, A, Hey, E, Neilson, J, Simon, J, Collins, R, Karaoglou, A, Lilford, R, Moodley, J, Robson, S, Roberts, I, Rubin, P, Thornton, J, Twaddle, S, Villar, J, Walker, I, Watkins, C, Doyle, L, Bimbashi, A, Demalia, E, Gliozheni, O, Shpata, A, Karolinski, A, Lamas, M, Pesaresi, M, Wainer, V, Barbato, W, Paciocco, M, Bertin, M, Boiza, E, Castaldi, J, Partida, Y, Arias, C, Farri, M, Kerz, G, Aguirre, J, de Sagastizabal, M, Falcone, R, Morales, E, Carroli, G, Krupitzky, S, Lopez, S, Palermo, M, Varela, DM, Delprato, H, Camusso, H, Curioni, M, Ludmer, E, Brandi, R, Martin, R, Mesas, W, Taralli, R, Lezaola, M, Morosini, M, Andina, E, Bernal, L, Estiu, M, Ulens, E, de Speranza, BO, Peyrano, A, Damiano, M, Saumench, C, Horn, J, Pritchard, M, Smith-Orr, V, Wilson, M, Lawrence, A, Watson, D, Crowther, C, Paynter, J, Ashrafunnessa, Mannan, M, Shahidullah, M, Shamsuddin, L, Santos, CB, Freire, S, Melo, E, Cobo, E, Jaramillo, M, Cardozo, C, Fandino, N, Gaitan, H, Montano, L, Lozano, J, Rojas, M, Garcia, AB, Ramirez, AF, Miras, RG, Sampera, S, Farnot, U, Gomez, E, Rojas, G, Valdes, R, El-Kreem, HA, Al-Hussaini, T, Hammad, E, Danso, K, Kwapong, E, Ofosu-Barko, F, Jasper, MP, Peedicayil, A, Regi, A, Sharma, R, Chauhan, A, Raut, V, Udani, R, Batra, S, Muthal-Rathore, A, Ramji, S, Zutshi, V, Balakrishnan, S, Eapen, E, Koshy, G, Ambardar, B, Vadakkepat, P, Vaidya, D, Lema, V, Rijken, Y, Tadesse, E, Dada, O, Sofekun, A, Ohiaeri, C, Runsewe-Abiodun, T, Adewole, I, Adeyemo, A, Brown, B, Oladokun, R, Adewale, O, Inimgba, N, John, C, Ogu, R, Ekele, B, Isah, A, Onankpa, B, Jamelle, R, Junejo, D, Faiz, N, Gul, F, Sherin, A, Bangash, K, Mahmud, G, Masud, K, Tasneem, N, Gassama, S, Soyei, A, Agarwal, P, Rajadurai, V, Pirani, N, Delport, S, Macdonald, P, Mokhondo, R, Pattinson, R, Zondo, M, Adhikari, M, Mnguni, N, Carstens, M, Kirsten, G, Steyn, W, van Zyl, J, Helwig, A, Jacobson, S-L, Panosche, R, Hammond, E, and Masanganise, L
- Abstract
OBJECTIVE: The aim of this study was to assess long-term effects for women following the use of magnesium sulphate for pre-eclampsia. DESIGN: Assessment at 2-3 years after delivery for women recruited to the Magpie Trial (recruitment in 1998-2001, ISRCTN 86938761), which compared magnesium sulphate with placebo for pre-eclampsia. SETTING: Follow up after discharge from hospital at 125 centres in 19 countries across five continents. POPULATION: A total of 7927 women were randomised at the follow-up centres. Of these women, 2544 were not included for logistic reasons and 601 excluded (109 at a centre where <20% of women were contacted, 466 discharged without a surviving child and 26 opted out). Therefore, 4782 women were selected for follow-up, of whom 3375 (71%) were traced. METHODS: Questionnaire assessment was administered largely by post or in a dedicated clinic. Interview assessment of selected women was performed. Main outcome measures Death or serious morbidity potentially related to pre-eclampsia at follow up, other morbidity and use of health service resources. RESULTS: Median time from delivery to follow up was 26 months (interquartile range 19-36). Fifty-eight of 1650 (3.5%) women allocated magnesium sulphate died or had serious morbidity potentially related to pre-eclampsia compared with 72 of 1725 (4.2%) women allocated placebo (relative risk 0.84, 95% CI 0.60-1.18). CONCLUSIONS: The reduction in the risk of eclampsia following prophylaxis with magnesium sulphate was not associated with an excess of death or disability for the women after 2 years.
- Published
- 2007
11. O614 Non‐pneumatic anti‐shock garment (NASG) reduces extreme adverse outcomes from obstetric hemorrhage and shock in Egyptian hospitals
- Author
-
Miller, S., primary, Mourad‐Youssif, M., additional, Fathalla, M., additional, Al‐Hussaini, T., additional, Meyer, C., additional, Camlin, C., additional, Butrick, E., additional, and Ismail, S., additional
- Published
- 2009
- Full Text
- View/download PDF
12. O296 Non‐atonic obstetric hemorrhage: Will the non‐pneumatic anti‐shock garment (NASG) help?
- Author
-
Fathalla, M., primary, Mourad‐Youssif, M., additional, Al‐Hussaini, T., additional, Turan, J., additional, Thompson, M., additional, Meyer, C., additional, Pabst, M., additional, and Miller, S., additional
- Published
- 2009
- Full Text
- View/download PDF
13. O641 Treatment with non-pneumatic anti-shock garment (NASG) improves outcomes for women with PPH/uterine atony in Egyptian referral facilities
- Author
-
Mourad-Youssif, M., primary, Fathalla, M., additional, Al-Hussaini, T., additional, Martin, H., additional, Turan, J., additional, Mitchell, R., additional, Camlin, C., additional, and Miller, S., additional
- Published
- 2009
- Full Text
- View/download PDF
14. Reactive oxygen species: a biological marker for early embryonic development in intracytoplasmic sperm injection (ICSI) cycles
- Author
-
Bedaiwy, Mohamed A, primary, Falcone, Tommaso, additional, Miller, Kurt, additional, Abdel-Aleem, A, additional, Al-Hussaini, T, additional, and Agarwal, Ashok, additional
- Published
- 2002
- Full Text
- View/download PDF
15. Use of semen quality scores in advising patients with male factor infertility considering intrauterine insemination.
- Author
-
Bedaiwy, M.A, primary, Al-Hussaini, T, additional, Mohamed, M.S, additional, Abdel-Aleem, A.M, additional, Nelson, D.R, additional, and Agarwal, A, additional
- Published
- 2001
- Full Text
- View/download PDF
16. Premature ovarian failure/dysfunction following surgical treatment of polycystic ovarian syndrome: A case series.
- Author
-
Al-Hussaini, T. K., Zakhera, M. S., Abdel-Aleem, M., and Abbas, A. M.
- Subjects
- *
PREMATURE ovarian failure , *POLYCYSTIC ovary syndrome , *FERTILITY clinics - Abstract
Polycystic ovarian syndrome (PCOS) is one of the most common causes of infertility in women. Surgical treatment of PCOS, either by the antiquated wedge resection or ovarian drilling, is one of the commonly used lines in developing countries due to its low-cost. Premature ovarian failure and diminished ovarian reserve are serious complications of the surgical treatment but no published reports sufficiently highlighted these hazards. In this case series, we report on twenty one women aged between 19-39 years, presented to Infertility Clinic, Assiut Women Health Hospital with ovarian dysfunction, diagnosed within 6-36 months after surgical management of PCOS. Nineteen of them had laparoscopic bilateral ovarian drilling using electrocauterization, and the last two had bilateral wedge resection of the ovaries through minilaparotomy. Accurate and documented diagnosis of PCOS, appropriate surgical training, adjusted thermal injury and adjusted number of punctures are essential for the avoidance of excessive damage to the ovaries. Under treatment (failure of drilling) is much better than premature ovarian failure or diminishing ovarian reserve. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
17. Three steps management of irreducible complete procidentia complicated by vesical calculi
- Author
-
Al-Hussaini, T. K., primary and Abol-Ella, H. A., additional
- Published
- 1999
- Full Text
- View/download PDF
18. Investigation on Active Isolation of Machine Foundations by Open Trenches
- Author
-
Ahmad, S., primary, Al-Hussaini, T. M., additional, and Fishman, K. L., additional
- Published
- 1996
- Full Text
- View/download PDF
19. Active Isolation of Machine Foundations by In-Filled Trench Barriers
- Author
-
Al-Hussaini, T. M., primary and Ahmad, S., additional
- Published
- 1996
- Full Text
- View/download PDF
20. Simplified Design for Vibration Screening by Open and In‐Filled Trenches
- Author
-
Ahmad, S., primary and Al‐Hussaini, T. M., additional
- Published
- 1991
- Full Text
- View/download PDF
21. Recurrent ectopic pregnancy following in-vitro fertilization.
- Author
-
al-Hussaini, T and Mettler, L
- Published
- 1992
22. The Cost Implications in Ontario, Alberta, and British Columbia of Early Versus Delayed External Cephalic Version in the Early External Cephalic Version 2 (EECV2) Trial
- Author
-
Ahmed, Rashid J., Gafni, Amiram, Hutton, Eileen K., Hutton, E.K., Barrett, J., Carson, G.D., Delisle, M.F., Dunn, M., Edwards, S., Fernandez, A., Gafni, A., Hannah, M.E., Hewson, S., Natale, R., Ohlsson, A., Ross, S.J., Willan, A.R., Windrim, R., Pollard, J.K., Schweitzer, Sylvestre, G., Turtle, P., Bracken, M., Crowley, P., Donner, A., Duley, L., Ehrenkranz, R., Curioni, M., Abalos Gorostiaga, R., Becker, C., Elizabeth, P.A., Errandonea, L., Palermo, M., Ramos, C.A., Trabucco, M., Montes Varela, D., Bertin, M.S., Castaldi, J.L., Mohedano de Duhalde, M., Becker, C., Messina, A., Baumgartner, J., Kovacs, G., Malcolm, B., Neil, J.R., Mahomed, K., Green, A., Child, A., DeVries, B., Phipps, H., Welsh, A., Davis, G.K., Roberts, L., Watts, N.P., Cybulski, M., Gibson, D., Tucker, S., McCahon, I., Sheehan, P., Umstad, M., Milligan, J., Morris, J., Rickard, K., Gardener, G., Jenkins-Manning, S., Boniface, C., Edmondson, M., Watson, D., Ayub, A., Delisle, M.F., Soanes, S., Jordan, A., Windrim, R., Fanning, C., Parish, B., Natale, R., Watson, M.A., Reid, D., Scheufler, P., Malott, A.M., Reitsma, A., Haslauer, K.A., Lipp, M., Farquharson, D., Gray, K., Demianczuk, N., Penttinen, E., Herer, E., McLean, K., Aghajafari, F., Williams, S., Moravac, C., Yudin, M., Pollard, J., Miller, L., Anderson, R.B., Good, M., Walker, M.C., Kulkarni, R., Scarfone, R., Cameron, C., Peel, T., Carrillo, J., Cruces, A., Gonzalez, Y., Figueroa Poblete, J., Lama Hormazabal, L., Saez, J., Oyarzun, E., Rioseco, A., Illanes, S., Kottmann, C., Parra, M., Quezada, S., Quiroz, L., Hvidman, L., Mogensen, I.M., Mouritzen, A., Ostberg, B., Abdel-Samad, S.N.M., Al-Hussaini, T., El-Nashar, I., Kirss, F., Rull, K., Ustav, E., Vaas, P., Brink-Spalink, V., Weizsaecker, K., Major, T., Poka, R., Daly, S., Kaneti, H., Rosen, D., Schachter, B., Chayen, B., Harel, L., Hiaeb, Z., Malinger, G., Dukler, D., Lunenfeld, E., AlFaris, L., El-Zibdeh, M., Domzalska-Popadiuk, I., Kobiela, P., Pankrac, Z., Preis, J., Preis, K., Swiatkowska-Freund, M., Cravo, J., Theron, A.M., Theron, G.B., Cronje, H.S., du Plessis, J.M., Munoz, M., Khan, G., Khan, S., Goossens, S., Pieters, M., Roumen, F.J.M.E., ten Cate, F., Pieters, M., Smits, F., Heres, M., Krabbendam, E., Airey, R., Farrar, D., Tuffnell, D.J., Heyes, V., Melvin, C., Schram, C., Galimberti, A., Stewart, P., Cresswell, J., McCormick, C., Andrews, J., Fleener, D., Coonrod, D., Jimenez, B.F., Brown, S., Gregg, A., Pitchford, C., and Seubert, D.
- Abstract
According to the Early External Cephalic Version (EECV2) Trial, planning external cephalic version (ECV) early in pregnancy results in fewer breech presentations at delivery compared with delayed external cephalic version. A Cochrane review conducted after the EECV2 Trial identified an increase in preterm birth associated with early ECV. We examined whether a policy of routine early ECV (i.e., before 37 weeks' gestation) is more or less costly than a policy of delayed ECV.
- Published
- 2016
- Full Text
- View/download PDF
23. Uterine rupture in second trimester abortion in a grand multiparous woman
- Author
-
Al-Hussaini, T. K.
- Published
- 2001
- Full Text
- View/download PDF
24. Hyperreactio luteinalis associated with normal singleton pregnancy.
- Author
-
Abdel-Aleem, H., Al-Hussaini, T., and Karoush, S.
- Subjects
- *
OVARIES , *PREGNANCY complications - Abstract
Reports a case of hyperreactio luteinalis associated with normal singleton pregnancy. Description of hyperreactio luteinalis; Clinical and ultrasound examination; Treatment.
- Published
- 2000
- Full Text
- View/download PDF
25. Multifactorial contributors to the severity of chronic pelvic pain in women.
- Author
-
Yosef A, Allaire C, Williams C, Ahmed AG, Al-Hussaini T, Abdellah MS, Wong F, Lisonkova S, and Yong PJ
- Subjects
- Abdominal Wall, Adult, Body Mass Index, British Columbia epidemiology, Chronic Pain epidemiology, Cohort Studies, Constipation epidemiology, Constipation physiopathology, Cross-Sectional Studies, Dysmenorrhea epidemiology, Dysmenorrhea physiopathology, Dyspareunia epidemiology, Dyspareunia physiopathology, Female, Humans, Pain Measurement, Pelvic Floor, Pelvic Pain epidemiology, Prospective Studies, Severity of Illness Index, Surveys and Questionnaires, Abdominal Pain epidemiology, Catastrophization epidemiology, Chronic Pain physiopathology, Cystitis, Interstitial epidemiology, Endometriosis epidemiology, Pelvic Pain physiopathology, Sex Offenses statistics & numerical data, Smoking epidemiology
- Abstract
Background: Chronic pelvic pain affects ∼15% of women, and is associated with significant societal cost and impact on women's health. Identifying factors involved in chronic pelvic pain is challenging due to its multifactorial nature and confounding between potential factors. For example, while some women with endometriosis have chronic pelvic pain, there may be comorbid conditions that are implicated in the chronic pelvic pain rather than the endometriosis itself., Objective: We sought to explore multifactorial variables independently associated with the severity of chronic pelvic pain in women., Study Design: We used baseline cross-sectional data from an ongoing prospective cohort, collected from patient online questionnaires, physical examination, and physician review of medical records. Participants were recruited from a tertiary referral center for endometriosis and chronic pelvic pain in Vancouver, British Columbia, Canada, from December 2013 through April 2015. Exclusion criteria included menopausal status or age >50 years. Primary outcome was self-reported severity of chronic pelvic pain in the last 3 months (0-10 numeric rating scale). Potential associated factors ranged from known pain conditions assessed by standard diagnostic criteria, validated psychological questionnaires, musculoskeletal physical exam findings, as well as pain-related, reproductive, medical/surgical, familial, demographic, and behavioral characteristics. Mann-Whitney, Kruskal-Wallis, or Spearman test were used to identify variables with an association with the primary outcome (P < .05), followed by multivariable linear regression to control for confounding and to identify independent associations with the primary outcome (P < .05)., Results: Overall, 656 women were included (87% consent rate), of whom 55% were diagnosed with endometriosis. The following factors were independently associated with higher severity of chronic pelvic pain: abdominal wall pain (P = .005), pelvic floor tenderness (P = .004), painful bladder syndrome (P = .019), higher score on Pain Catastrophizing Scale (P < .001), adult sexual assault (P = .043), higher body mass index (P = .023), current smoking (P = .049), and family history of chronic pain (P = .038). Severity of chronic pelvic pain was similar between women with and without endometriosis., Conclusion: Multifactorial variables independently associated with severity of chronic pelvic pain were identified, ranging from myofascial/musculoskeletal, urological, family history, and psycho-social factors. Continued research is required to validate these factors and to determine whether any are potentially modifiable for the management of chronic pelvic pain., (Copyright © 2016 Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
26. No evidence for mutations in NLRP7 and KHDC3L in women with androgenetic hydatidiform moles.
- Author
-
Mahadevan S, Wen S, Balasa A, Fruhman G, Mateus J, Wagner A, Al-Hussaini T, and Van den Veyver IB
- Subjects
- Base Sequence, Case-Control Studies, DNA Mutational Analysis, Female, Humans, Inheritance Patterns genetics, Mutation, Polymorphism, Single Nucleotide, Pregnancy, Adaptor Proteins, Signal Transducing genetics, Hydatidiform Mole genetics, Proteins genetics, Uterine Neoplasms genetics
- Abstract
Objective: The objective of this study was to evaluate the mutational spectrum of NLRP7 and KHDC3L (C6orf221) in women with sporadic and recurrent androgenetic complete hydatidiform moles (AnCHM) and biparental hydatidiform moles (BiHM) to address the hypothesis that autosomal recessive mutations in these genes are only or primarily associated with BiHM., Method: We recruited 16 women with suspected recurrent and sporadic AnCHM and five women with suspected BiHM in addition to their reproductive partners into our study. We then sequenced the coding exons of NLRP7 and KHDC3L from DNA isolated from either blood or saliva from the study subjects., Results: Sequence analysis of NLRP7 and KHDC3L revealed previously described single nucleotide polymorphisms in patients with AnCHM. However, in patients with BiHM, we identified a novel homozygous mutation and a previously described intragenic duplication of exons 2 to 5 in NLRP7, both of which are likely to be disease causing. We did not identify mutations in KHDC3L in patients with either form of hydatidiform moles., Conclusions: The absence of mutations in women with AnCHM supports a role for NLRP7 or KHDC3L in BiHM only. The absence of mutations in KHDC3L in women with BiHM is consistent with its minor role in this disease compared with NLRP7, the major BiHM gene., (© 2013 John Wiley & Sons, Ltd.)
- Published
- 2013
- Full Text
- View/download PDF
27. Obstetric hemorrhage and shock management: using the low technology Non-pneumatic Anti-Shock Garment in Nigerian and Egyptian tertiary care facilities.
- Author
-
Miller S, Fathalla MM, Ojengbede OA, Camlin C, Mourad-Youssif M, Morhason-Bello IO, Galadanci H, Nsima D, Butrick E, Al Hussaini T, Turan J, Meyer C, Martin H, and Mohammed AI
- Subjects
- Egypt, Female, Health Facilities, Health Resources, Humans, Maternal Mortality, Nigeria, Obstetric Labor Complications blood, Pregnancy, Clothing, Obstetric Labor Complications therapy, Shock therapy, Uterine Hemorrhage therapy
- Abstract
Background: Obstetric hemorrhage is the leading cause of maternal mortality globally. The Non-pneumatic Anti-Shock Garment (NASG) is a low-technology, first-aid compression device which, when added to standard hypovolemic shock protocols, may improve outcomes for women with hypovolemic shock secondary to obstetric hemorrhage in tertiary facilities in low-resource settings., Methods: This study employed a pre-intervention/intervention design in four facilities in Nigeria and two in Egypt. Primary outcomes were measured mean and median blood loss, severe end-organ failure morbidity (renal failure, pulmonary failure, cardiac failure, or CNS dysfunctions), mortality, and emergency hysterectomy for 1442 women with ≥750 mL blood loss and at least one sign of hemodynamic instability. Comparisons of outcomes by study phase were assessed with rank sum tests, relative risks (RR), number needed to treat for benefit (NNTb), and multiple logistic regression., Results: Women in the NASG phase (n = 835) were in worse condition on study entry, 38.5% with mean arterial pressure <60 mmHg vs. 29.9% in the pre-intervention phase (p = 0.001). Despite this, negative outcomes were significantly reduced in the NASG phase: mean measured blood loss decreased from 444 mL to 240 mL (p < 0.001), maternal mortality decreased from 6.3% to 3.5% (RR 0.56, 95% CI 0.35-0.89), severe morbidities from 3.7% to 0.7% (RR 0.20, 95% CI 0.08-0.50), and emergency hysterectomy from 8.9% to 4.0% (RR 0.44, 0.23-0.86). In multiple logistic regression, there was a 55% reduced odds of mortality during the NASG phase (aOR 0.45, 0.27-0.77). The NNTb to prevent either mortality or severe morbidity was 18 (12-36)., Conclusion: Adding the NASG to standard shock and hemorrhage management may significantly improve maternal outcomes from hypovolemic shock secondary to obstetric hemorrhage at tertiary care facilities in low-resource settings.
- Published
- 2010
- Full Text
- View/download PDF
28. Can the Non-pneumatic Anti-Shock Garment (NASG) reduce adverse maternal outcomes from postpartum hemorrhage? Evidence from Egypt and Nigeria.
- Author
-
Mourad-Youssif M, Ojengbede OA, Meyer CD, Fathalla M, Morhason-Bello IO, Galadanci H, Camlin C, Nsima D, Al Hussaini T, Butrick E, and Miller S
- Abstract
Background: Postpartum hemorrhage (PPH) is the leading cause of maternal mortality and severe maternal morbidity. The Non-pneumatic Anti-Shock Garment (NASG), a first-aid lower-body compression device, may decrease adverse outcomes from obstetric hemorrhage. This article is the first to report the effect of the NASG for PPH., Methods: This pre-intervention/NASG study of 854 women was conducted in four referral facilities in Nigeria and two in Egypt between 2004-2008. Entry criteria were women with PPH due to uterine atony, retained placenta, ruptured uterus, vaginal or cervical lacerations or placenta accreta with estimated blood loss of ≥ 750 mL and one clinical sign of shock. Differences in demographics, conditions on study entry, treatment and outcomes were examined. The Wilcoxon rank-sum test and relative risks with 95% confidence intervals were calculated for primary outcomes - measured blood loss, emergency hysterectomy, mortality, morbidity (each individually), and a combined variable, "adverse outcomes", defined as severe morbidity and mortality. A multiple logistic regression model was fitted to test the independent association between the NASG and the combined severe morbidity and mortality outcome., Results: Measured blood loss decreased by 50% between phases; women experienced 400 mL of median blood loss after study entry in the pre-intervention and 200 mL in the NASG phase (p < 0.0001). As individual outcomes, mortality decreased from 9% pre-intervention to 3.1% in the NASG phase (RR 0.35, 95% CI 0.19-0.62); severe morbidity decreased from 4.2% to 1%, in the NASG phase (RR 0.24, 95% CI 0.09-0.67). As a combination, "adverse outcomes," decreased from 12.8% to 4.1% in the NASG phase (RR 0.32, 95% CI 0.19-0.53). In a multiple logistic regression model, the NASG was associated with the combined outcome of severe maternal morbidity and mortality (OR 0.42, 95% CI 0.18-0.99)., Conclusion: In this non-randomized study, in which bias is inherent, the NASG showed promise for reducing blood loss, emergency hysterectomy, morbidity and mortality associated with PPH in referral facilities in Egypt and Nigeria.
- Published
- 2010
- Full Text
- View/download PDF
29. A recurrent intragenic genomic duplication, other novel mutations in NLRP7 and imprinting defects in recurrent biparental hydatidiform moles.
- Author
-
Kou YC, Shao L, Peng HH, Rosetta R, del Gaudio D, Wagner AF, Al-Hussaini TK, and Van den Veyver IB
- Subjects
- DNA Methylation, Egypt, Exons genetics, Female, Gene Duplication, Humans, Hydatidiform Mole pathology, Male, Point Mutation, Pregnancy, Reverse Transcriptase Polymerase Chain Reaction, Adaptor Proteins, Signal Transducing genetics, Genomic Imprinting genetics, Hydatidiform Mole genetics, Mutation
- Abstract
A complete hydatidiform mole (CHM) is an abnormal pregnancy with hyperproliferative vesicular trophoblast and no fetal development. Most CHM are sporadic and androgenetic, but recurrent HM have biparental inheritance (BiHM) with disrupted DNA methylation at differentially methylated regions (DMRs) of imprinted loci. Some women with recurrent BiHM have mutations in the NLRP7 gene on chromosome 19q13.42. Using bisulfite genomic sequencing at eight imprinted DMRs on DNA from two BiHMs, we found a pattern of failure to acquire or maintain DNA methylation at DMRs (PEG3, SNRPN, KCNQ1OT1, GNAS exon 1A) that normally acquire CpG methylation during oogenesis, but not at H19, which acquires CpG methylation during spermatogenesis. Secondary imprints at the GNAS locus showed variable abnormal patterns with both gain and loss of CpG methylation. We found novel missense and splice-site mutations in NLRP7 in women with non-familial recurrent BiHM. We identified and characterized a homozygous intragenic tandem duplication including exons 2 through 5 of NLRP7 that results in a predicted truncated protein in affected women of three unrelated Egyptian kindreds, suggesting a founder effect. Our findings firmly establish that NLRP7 mutations are a major cause of BiHM and confirm presence of a complex pattern of imprinting abnormalities in BiHM tissues.
- Published
- 2008
- Full Text
- View/download PDF
30. Biparental hydatidiform moles: a maternal effect mutation affecting imprinting in the offspring.
- Author
-
Van den Veyver IB and Al-Hussaini TK
- Subjects
- Chromatin metabolism, DNA Methylation, Female, Humans, Hydatidiform Mole classification, Hydatidiform Mole diagnosis, Mutation, Pregnancy, Uterine Neoplasms classification, Uterine Neoplasms diagnosis, Genes, Recessive genetics, Genomic Imprinting, Hydatidiform Mole genetics, Pregnancy Complications genetics, Uterine Neoplasms genetics
- Abstract
Highly recurrent hydatidiform moles (HMs) studied to date are not androgenetic but have biparental genomic contribution (BiHM). Affected women have an autosomal recessive mutation that causes their pregnancies to develop into HM. Although there is genetic heterogeneity, a major locus maps to chromosome 19q13.42, but a mutated gene has not yet been identified. Molecular studies have shown that maternal imprinting marks are deregulated in the BiHM trophoblast. The mutations that cause this condition are, therefore, hypothesized to occur in genes that encode transacting factors required for the establishment of imprinting marks in the maternal germline or for their maintenance in the embryo. Although only DNA methylation marks at imprinted loci have been studied in the BiHM, the mutation may affect genes that are essential for other forms of chromatin remodelling at imprinted loci and necessary for correct maternal allele-specific DNA methylation and imprinted gene expression. Normal pregnancies interspersed with BiHM have been reported in some of the pedigrees, but affected women repeatedly attempting pregnancy should be counselled about the risk for invasive trophoblastic disease with each subsequent BiHM.
- Published
- 2006
- Full Text
- View/download PDF
31. Recurrent pregnancy loss due to familial and non-familial habitual molar pregnancy.
- Author
-
Al-Hussaini TK, Abd el-Aal DM, and Van den Veyver IB
- Subjects
- Adult, Female, Genetic Predisposition to Disease, Humans, Pedigree, Pregnancy, Abortion, Habitual genetics, Hydatidiform Mole genetics, Pregnancy Complications, Neoplastic etiology, Uterine Neoplasms genetics
- Abstract
Objectives: To present a series of women with recurrent molar pregnancies, including rare familial cases, and discuss etiology and treatment options., Methods: We performed a detailed clinical evaluation and pedigree analysis of five Egyptian women with recurrent pregnancy loss due to molar pregnancy., Results: The women had a history of four to nine consecutive hydatidiform moles but of no viable pregnancies. Two of the women had molar pregnancies with different husbands who themselves had viable offspring from previous wives; and three of them, who belonged to a family with extensive intermarriage, had a pedigree consistent with an autosomal recessive maternal-effect mutation., Conclusions: Recurrent pregnancy loss due to habitual molar pregnancy is uncommon and familial cases are extremely rare. The etiology of this disorder is not well understood but likely results from a maternal-effect mutation. Management options are limited, especially for couples who desire to have their own genetic offspring.
- Published
- 2003
- Full Text
- View/download PDF
32. Second-trimester pregnancy termination: comparison of three different methods.
- Author
-
Makhlouf AM, Al-Hussaini TK, Habib DM, and Makarem MH
- Subjects
- Abortifacient Agents administration & dosage, Administration, Intravaginal, Adult, Analgesia, Contraindications, Dinoprostone administration & dosage, Female, Humans, Misoprostol administration & dosage, Nitroglycerin administration & dosage, Pregnancy, Pregnancy Trimester, Second, Abortion, Induced methods, Gestational Age
- Abstract
The object of this study was to compare intravaginal misoprostol and dinoprostone (prostaglandin E2) for second-trimester pregnancy termination, and to examine the role of the nitric oxide donor, glyceryl trinitrate, as a possible alternative to prostaglandins to induce cervical ripening in second-trimester pregnancy termination. This was a randomised clinical trial. The trial involved pregnant women between 13 and 28 weeks' gestation admitted with clear medical or obstetric indications for pregnancy termination, and was carried out in the department of obstetrics and gynecology, Assiut University Hospital, Egypt. Patients were classified into Group A, where pregnancy termination was induced by vaginal misoprostol 100 micrograms every 4 hours with a maximum dose of 500 micrograms; Group B, where induction was by vaginal dinoprostone 6 mg every 6 hours with a maximum dose of 24 mg; and Group C, where induction involved vaginal glyceryl trinitrate 500 micrograms every 6 hours with a maximum dose of 2.5 mg. Twenty-four hours after the start of induction, the rate of complete abortion in the three groups was 100%, 66.67% and 0%, respectively. The rate of complete abortion was 100% in the nitric oxide (glyceryl trinitrate)-induced group after introducing a complementary procedure. The induction-abortion interval was significantly shorter, the number of doses needed was less and the maximum Bishop score reached was greater with misoprostol than with dinoprostone. A higher rate of side effects occurred with the misoprostol-induced group (74%) compared with the other two groups (46.6% and 0%). Misoprostol is a cheap, effective drug for second-trimester pregnancy termination with short induction abortion intervals but a higher rate of side effects. Prostin E2 is also effective in termination of second-trimester pregnancy but is expensive and may require high doses to be administered. Glyceryl trinitrate is an effective drug for cervical ripening (softening) but it has no role in the stimulation of uterine contractions.
- Published
- 2003
- Full Text
- View/download PDF
33. Oral misoprostol vs. intravenous oxytocin for labor induction in women with prelabor rupture of membranes at term.
- Author
-
Al-Hussaini TK, Abdel-Aal SA, and Youssef MA
- Subjects
- Administration, Oral, Female, Humans, Infusions, Intravenous, Pregnancy, Time Factors, Treatment Outcome, Fetal Membranes, Premature Rupture drug therapy, Labor, Induced methods, Misoprostol administration & dosage, Oxytocics administration & dosage, Oxytocin administration & dosage
- Published
- 2003
- Full Text
- View/download PDF
34. Uterine rupture in second trimester abortion in a grand multiparous woman. A complication of misoprostol and oxytocin.
- Author
-
Al-Hussaini TK
- Subjects
- Abdominal Pain, Abortifacient Agents administration & dosage, Administration, Intravaginal, Adult, Female, Gestational Age, Humans, Hysterectomy, Misoprostol administration & dosage, Misoprostol adverse effects, Oxytocin administration & dosage, Parity, Pregnancy, Uterine Rupture diagnosis, Uterine Rupture surgery, Abortion, Induced adverse effects, Fetal Death, Uterine Rupture etiology
- Abstract
Rupture of unscarred uterus during the second trimester is rare. There have been only 32 cases reported in the literature since 1968. A case of ruptured uterus in a grand multiparous woman is presented. To our knowledge, this might be the first reported case in the English literature of uterine rupture during second trimester termination of pregnancy using a prostaglandin E1 analogue (Misoprostol) and oxytocin.
- Published
- 2001
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.